Detailed Information

Cited 0 time in webofscience Cited 12 time in scopus
Metadata Downloads

Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis

Authors
Sohn, H. S.Kwon, J. -W.Shin, S.Kim, H. -S.Kim, H.
Issue Date
Dec-2015
Publisher
WILEY
Keywords
erlotinib; gefitinib; non-small cell lung cancer; smoking
Citation
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, v.40, no.6, pp 661 - 671
Pages
11
Journal Title
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
Volume
40
Number
6
Start Page
661
End Page
671
URI
https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/10153
DOI
10.1111/jcpt.12332
ISSN
0269-4727
1365-2710
Abstract
What is known and objective: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as erlotinib or gefitinib are indicated for the treatment of non-small cell lung cancer (NSCLC). EGFR tyrosine kinase domain mutations have been reported to be associated with EGFR-TKI response in patients with NSCLC. Certain patient subgroups in which EGFR somatic mutations are more frequently observed are thought to derive more clinical benefit from EGFR-TKI therapy. We performed a systematic review and meta-analysis to summarize the evidence regarding the association of smoking status with overall survival (OS) and progression-free survival (PFS) in patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib. Methods: Eligible studies were selected by two independent reviewers using the inclusion and exclusion criteria predefined in the protocol. Eligible studies included those evaluating the association of smoking status with OS and PFS in patients with NSCLC receiving erlotinib or gefitinib. Non-clinical studies, case reports, non-peer-reviewed abstracts and non-relevant studies were excluded. Results and discussion: Data on OS and PFS in patients with NSCLC treated with EGFR-TKIs were available in nine and ten trials, respectively. The OS and PFS from both the treatment and control groups were not significantly different between never smokers and former or current smokers (OS: odds ratio [OR], 0.80; 95% confidence interval [CI], 0.63-1.09; PFS: OR, 0.75; 95% CI, 0.49-1.14), respectively. However, in comparison within each smoking group, EGFR-TKI treatment led to more favourable OS and PFS in neversmokers (OS: OR, 0.55; 95% CI, 0.42.0.73; PFS: OR, 0.43; 95% CI, 0.33.0.54), compared with former or current smokers (OS: OR, 0.89; 95% CI, 0.80.0.97; PFS: OR, 0.73; 95% CI, 0.62.0.85). What is new and conclusion: Among patients with NSCLC receiving EGFR-TKI therapy with erlotinib or gefitinib, never smokers appear to show longer OS and PFS as compared to former or current smokers. However, this is based on indirect comparisons and more robust larger head-to-head trials are required for more robust inferences.
Files in This Item
Go to Link
Appears in
Collections
약학대학 > 약학부 > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Kim, Hyun Ah photo

Kim, Hyun Ah
약학대학 (약학부)
Read more

Altmetrics

Total Views & Downloads

BROWSE